Health Care • Biotechnology: Pharmaceutical Preparations
$2.62 ▼ -0.08
(-2.96%)
MKT CAP: $216.5M • VOL: 314.8K
52W L $3 52W H $15
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
BBOT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$145.8M | -$80.9M | -$41.7K |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$134.0M | -$74.3M | -$41.7K |
| EBITDA (Normalized) | -$145.3M | -$80.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$113.9M | -$55.0M | — |
| Capital Expenditures (CapEx) | $606.0K | $49.0K | — |
| Free Cash Flow (FCF) | -$114.5M | -$55.1M | — |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $373.7M | $30.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $411.1M | -$178.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BBOT.